DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1939)

Epilepsy | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Partial Onset (US)

Epilepsy | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Partial Onset (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

DRG epidemiologists estimate that 60% of epilepsy patients experience partial-onset seizures (POS), which aretypically the gateway indication for new antiepileptic drugs (AEDs). The most frequently prescribed early-line treatments for POS are generic mainstays, such as levetiracetam, lamotrigine, and carbamazepine/oxcarbazepine; newer brands such as Vimpat and Briviact are prescribed in later lines of therapy, mostly to treatment-refractory patients. Neurologists consider many factors when selecting among the many first-, second-, and third-generation AEDs and make adjustments throughout a patient’s disease course to achieve optimal seizure control. Understanding the evolving journey of epilepsy patients with POS provides important context about the complex, saturated, and heavily generic market that developers of new AEDs will enter. For the first time, our 2019 Treatment Algorithms series offers this POS segmentation, as well as a companion study on generalized-onset seizures (GOS).

Questions Answered

  • What patient share do key generics and brands garner by line of therapy in newly diagnosed epilepsy patients with POS? What are the quarterly trends in prescribing among recently treated and newly diagnosed epilepsy patients with POS?
  • How have Briviact, Vimpat, and other third-generation brands been integrated into the treatment algorithm, and what is their source of business?
  • What proportion of newly diagnosed epilepsy patients with POS receive drug therapy during our tracking period, and how quickly do they receive it? What percentage of patients progress to later lines of therapy during our tracking period?
  • What percentage of epilepsy patients with POS are treated with monotherapy versus combination therapy? What are the most commonly used therapy combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients with POS?

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key companies: Sunovion Pharmaceuticals, Eisai, UCB, Pfizer, Janssen, and Concordia Pharmaceuticals

Key drugs covered: Vimpat, Aptiom, Briviact, Fycompa, Lyrica, levetiracetam, lamotrigine, carbamazepine, oxcarbazepine, valproates

Key analysis provided:

  • Brand / therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Partial Onset (US)
    • Treatment Algorithms CDA-Epilepsy (Partial-onset seizures)-US-April 2019

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): Niyati Khetarpal, Ph.D
  • "Niyati Khetarpal  is an analyst on the Central Nervous System, Pain, and Ophthalmology team at ;In this role, she conducts extensive secondary research to analyze and forecast pharmaceutical markets, with specific expertise in patent research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope ;

Purchase Report

Recent reports:
You may also be interested in: